Gottlieb's 2018 Generic Drug Approval Goal May Be In Doubt
Executive Summary
Thanks in large part to new elemental impurities requirements, ANDA approvals are behind the pace needed to beat 2017’s record.
You may also be interested in...
US FDA, USP Collaborate To Promote Generic Development In Reversal Of Biosimilar Clash
Talks remain in early stages, but both sides thinking 'outside the box' to come up with potential policy updates to generate more generic competition and bring down drug prices.
Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan
Bringing the hammer down on biopharma, HHS Secretary Azar says department could use demonstration projects to switch drugs from Medicare Part B to Part D.
Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.